Class Action Risks in Food Labeling: Changing Regulation, Consumer Litigation

Why Should You Attend:

Many recent consumer class action suits have resulted in multimillion dollar settlements and they are something to avoid. Even if a case is without merit, claims are being brought against food companies so it is necessary to keep up with these trends so you know what the consumer is targeting.

This webinar will review the trends so you know what to watch out for. Specifically we will outline the substance of claims brought by the Plaintiff – namely “natural,” “organic,” “value added ingredients,” health benefit statement, and standard of identity claims. This webinar will also review the evolution of class action suits, and issues that the consumer have overcome in certain jurisdictions, for example, standing, preemption, and class certification and we will also provide some suggestions that will help a firm avoid these types of cases.

This session is designed for food manufacturers and labelers and is focused towards helping both domestic and foreign entities.

Areas Covered in the Webinar:

• Class action complaints against food companies
• Settlement and other outcomes of class action claims against food companies
• Procedural issues in class action food claim cases
• “natural claims,” “organic claims”
• Potential changes in FDA regulations to address certain class action claims

Who Will Benefit:

Food and tobacco manufacturers and facilities responsible for packaging/labeling food products will benefit from this training. This webinar will provide valuable assistance to

• Regulatory affairs
• Food packaging suppliers and manufacturers
• Labeling
• Documentation
• Food technologists
• Marketing
• QA/ QC

Instructor Profile:

J Mason Weeda, is Associate Attorney at Olsson Frank Weeda. He devotes his practice to a blend of regulatory and litigation matters, principally representing medical device, biologics, pharmaceutical and food manufacturers, distributors and importers.

Mr. Weeda has worked in sales and marketing for a biologics manufacturer and a laboratory that provided neurogenetic diagnostic testing. Since receiving his juris doctorate, Mr. Weeda has advised clients on a wide array of topics ranging from the U.S. Food and Drug Administration (FDA) regulatory status of clinical trials to compliance with the complexities of the Health Insurance Portability and Accountability Act (HIPAA). In addition to maintaining a food, drug and device-based practice, Mr. Weeda represents clients in civil litigation matters.

Follow us :